Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Organisation › Details

Storm Therapeutics Ltd.

STORM Therapeutics is a University of Cambridge spin-out, translating the ground breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases. STORM Therapeutics is backed by blue chip investors Cambridge Innovation Capital, Merck Ventures, Pfizer Ventures and Touchstone Innovations, who share the founders’ ambitions to build a world-leading company in the field. The company raised its series A funding in June 2016 and occupies modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. *


Period Start 2016-06-28 splitoff before
  Predecessor University of Cambridge
Product Industry cancer drug
Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
  Street Moneta Building
Babraham Research Campus
  City CB22 3AT Cambridge, Cambridgeshire
  Tel +44-1223-804174
    Address record changed: 2017-07-27
Basic data Employees n. a.
    * Document for �About Section�: Storm Therapeutics Ltd.. (1/8/18). "Press Release: Storm Therapeutics Extends Series A Round to Include New Investor Taiho Ventures". Cambridge.
Record changed: 2020-01-11


Picture [iito] No Tracking 650x80px

More documents for Storm Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top